EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Using cell‐free RNA to identify B‐ and T‐cell clonality for diagnosis and monitoring of B‐ and T‐cell neoplasms

Adam Albitar, Sally Agersborg, Ahmed Charifa, Pooja Phull, Noa Biran, David Vesole, Harsh Parmar, Andrew Pecora, Andrew Ip iD, Andre Goy, David Siegel, Maher Albitar iD

FEBS Open Bio · 13.08.2026

DOI: 10.1002/2211-5463.70323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, online erschienen am 13.08.2026. Verfasst von Adam Albitar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Testing Cooperative, Lake Forest, CA, USA. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell‐free RNA (cfRNA) is emerging as a supplemental approach for liquid biopsy (LBx). Given that lymphoid cells and plasma cells express substantial quantities of immunoglobulin (Ig) and T‐cell receptor (TCR) RNA, we investigated the utility of using cfRNA for detecting B‐cell and T‐cell clonality in LBxs. Using next‐generation sequencing (NGS) of cfRNA, we clonotyped Igs and TCRs in LBx samples from patients with B‐cell neoplasm, T‐cell neoplasm, myeloid neoplasm and solid tumors alongside cancer‐free individuals. To establish a clonality cutoff, we clonotyped tissue RNA from patients with confirmed clonal B‐ or T‐cell and from polyclonal. Clonotype‐naïve testing of LBx samples demonstrated B‐cell clonality in 36% of B‐cell neoplasms, 7% of normal, 8% of T‐cell lymphomas, 13% of myeloid neoplasms, and 14% of solid tumors. T‐cell clonality using TCR beta or gamma demonstrated T‐cell clonality in 22% of T‐cell neoplasms, 3% of normal, 5% of myeloid neoplasms, 7% of solid tumors and 3% of B‐cell neoplasms. This confirms that Clonotype‐naïve cfRNA testing in LBx is a reliable approach for detecting B‐ and T‐cell clonality.

Schlagwörter

Stichwörter der Autor:innen

B‐cell clonalityT‐cell clonality. clonotypecell‐free RNAliquid biopsylymphoid neoplasm

Autor:innen und Institutionen

  • Genomic Testing Cooperative, Lake Forest, CA, USA.
  • John Theurer Cancer Center, Hackensack University Medical Center, NJ, USA.

ORCID-Profile: Andrew Ip, Maher Albitar

Zitieren

APA

Albitar, A., Agersborg, S., Charifa, A., Phull, P., Biran, N., Vesole, D., Parmar, H., Pecora, A., Ip, A., Goy, A., Siegel, D., & Albitar, M. (2026). Using cell‐free RNA to identify B‐ and T‐cell clonality for diagnosis and monitoring of B‐ and T‐cell neoplasms. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70323

Vancouver

Albitar A, Agersborg S, Charifa A, Phull P, Biran N, Vesole D, et al. Using cell‐free RNA to identify B‐ and T‐cell clonality for diagnosis and monitoring of B‐ and T‐cell neoplasms. FEBS Open Bio. 2026. doi:10.1002/2211-5463.70323

BibTeX
@article{Albitar2026,
  author = {Albitar, Adam and Agersborg, Sally and Charifa, Ahmed and Phull, Pooja and Biran, Noa and Vesole, David and Parmar, Harsh and Pecora, Andrew and Ip, Andrew and Goy, Andre and Siegel, David and Albitar, Maher},
  title = {Using cell‐free RNA to identify B‐ and T‐cell clonality for diagnosis and monitoring of B‐ and T‐cell neoplasms},
  journal = {FEBS Open Bio},
  year = {2026},
  doi = {10.1002/2211-5463.70323}
}
Kostenlos starten →